{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:22:56Z","timestamp":1790662976308,"version":"4.1.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB\/TR-209"],"award-info":[{"award-number":["SFB\/TR-209"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70111929"],"award-info":[{"award-number":["70111929"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatocellular carcinoma (HCC) represents a global health challenge with limited therapeutic options. Anti-angiogenic immune checkpoint inhibitor-based combination therapy has been introduced for progressed HCC, but improves survival only in a subset of HCC patients. Tyrosine-kinase inhibitors (TKI) such as sorafenib represent an alternative treatment option but have only modest efficacy. Using different HCC cell lines and HCC tissues from various patients reflecting HCC heterogeneity, we investigated whether the sorafenib response could be enhanced by combination with pro-apoptotic agents, such as TNF-related apoptosis-inducing ligand (TRAIL) or the BH3-mimetic ABT-737, which target the death receptor and mitochondrial pathway of apoptosis, respectively. We found that both agents could enhance sorafenib-induced cell death which was, however, dependent on specific BH3-only proteins. TRAIL augmented sorafenib-induced cell death only in NOXA-expressing HCC cells, whereas ABT-737 enhanced the sorafenib response also in NOXA-deficient cells. ABT-737, however, failed to augment sorafenib cytotoxicity in the absence of BIM, even when NOXA was strongly expressed. In the presence of NOXA, BIM-deficient HCC cells could be in turn strongly sensitized for cell death induction by the combination of sorafenib with TRAIL. Accordingly, HCC tissues sensitive to apoptosis induction by sorafenib and TRAIL revealed enhanced NOXA expression compared to HCC tissues resistant to this treatment combination. Thus, our results suggest that BH3-only protein expression determines the treatment response of HCC to different sorafenib-based drug combinations. Individual profiling of BH3-only protein expression might therefore assist patient stratification to certain TKI-based HCC therapies.<\/jats:p>","DOI":"10.1038\/s41419-021-04020-z","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T06:02:28Z","timestamp":1627279348000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment"],"prefix":"10.1038","volume":"12","author":[{"given":"Stephanie","family":"Busche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Wandrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian W. R.","family":"Vondran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2350-6584","authenticated-orcid":false,"given":"Ulrich","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4369-8456","authenticated-orcid":false,"given":"Frank","family":"Essmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1443-2720","authenticated-orcid":false,"given":"Klaus","family":"Schulze-Osthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Bantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"key":"4020_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2021;7:6.","journal-title":"Nat Rev Dis Prim"},{"key":"4020_CR2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"4020_CR3","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"4020_CR4","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"4020_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000514312","volume":"10","author":"M Kudo","year":"2021","unstructured":"Kudo M. Sequential therapy for hepatocellular carcinoma after failure of atezolizumab plus bevacizumab combination therapy. Liver Cancer. 2021;10:85\u201393.","journal-title":"Liver Cancer"},{"key":"4020_CR6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jhep.2011.11.029","volume":"57","author":"M Malz","year":"2012","unstructured":"Malz M, Pinna F, Schirmacher P, Breuhahn K. Transcriptional regulators in hepatocarcinogenesis-key integrators of malignant transformation. J Hepatol. 2012;57:186\u201395.","journal-title":"J Hepatol"},{"key":"4020_CR7","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1158\/1078-0432.CCR-18-3778","volume":"25","author":"R Pinyol","year":"2019","unstructured":"Pinyol R, Sia D, Llovet JM. Immune exclusion-Wnt\/CTNNB1 class predicts resistance to immunotherapies in HCC. Clin Cancer Res. 2019;25:2021\u20133.","journal-title":"Clin Cancer Res"},{"key":"4020_CR8","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","volume":"9","author":"M Ruiz de Galarreta","year":"2019","unstructured":"Ruiz de Galarreta M, Bresnahan E, Molina-S\u00e1nchez P, Lindblad KE, Maier B, Sia D. et al. \u03b2-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 2019;9:1124\u201341.","journal-title":"Cancer Discov"},{"key":"4020_CR9","doi-asserted-by":"publisher","first-page":"6478","DOI":"10.1074\/jbc.M116.754184","volume":"292","author":"B Gillissen","year":"2017","unstructured":"Gillissen B, Richter A, Richter A, Preissner R, Schulze-Osthoff K, Essmann F, et al. Bax\/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma. J Biol Chem. 2017;292:6478\u201392.","journal-title":"J Biol Chem"},{"key":"4020_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ccr.2007.05.006","volume":"12","author":"MS Ricci","year":"2007","unstructured":"Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell. 2007;12:66\u201380.","journal-title":"Cancer Cell"},{"key":"4020_CR11","doi-asserted-by":"publisher","first-page":"9490","DOI":"10.1158\/0008-5472.CAN-07-0598","volume":"67","author":"RR Rosato","year":"2007","unstructured":"Rosato RR, Almenara JA, Coe S, Grant S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res. 2007;67:9490\u2013500.","journal-title":"Cancer Res"},{"key":"4020_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1440-1746.2010.06582.x","volume":"26","author":"JM Schattenberg","year":"2011","unstructured":"Schattenberg JM, Schuchmann M, Galle PR. Cell death and hepatocarcinogenesis: dysregulation of apoptosis signaling pathways. J Gastroenterol Hepatol. 2011;26:213\u20139. Suppl 1.","journal-title":"J Gastroenterol Hepatol"},{"key":"4020_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3389\/fphys.2012.00079","volume":"3","author":"H Bantel","year":"2012","unstructured":"Bantel H, Schulze-Osthoff K. Mechanisms of cell death in acute liver failure. Front Physiol. 2012;3:79.","journal-title":"Front Physiol"},{"key":"4020_CR14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1046\/j.1432-1327.1998.2540439.x","volume":"254","author":"K Schulze-Osthoff","year":"1998","unstructured":"Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, Peter ME. Apoptosis signaling by death receptors. Eur J Biochem. 1998;254:439\u201359.","journal-title":"Eur J Biochem"},{"key":"4020_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1042\/bse0390073","volume":"39","author":"PT Daniel","year":"2003","unstructured":"Daniel PT, Schulze-Osthoff K, Belka C, G\u00fcner D. Guardians of cell death: the Bcl-2 family proteins. Essays Biochem. 2003;39:73\u201388.","journal-title":"Essays Biochem"},{"key":"4020_CR16","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1038\/onc.2012.348","volume":"32","author":"SM Kilbride","year":"2013","unstructured":"Kilbride SM, Prehn JH. Central roles of apoptotic proteins in mitochondrial function. Oncogene. 2013;32:2703\u201311.","journal-title":"Oncogene"},{"key":"4020_CR17","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.3389\/fonc.2019.01421","volume":"9","author":"JU Marquardt","year":"2019","unstructured":"Marquardt JU, Edlich F. Predisposition to apoptosis in hepatocellular carcinoma: from mechanistic insights to therapeutic strategies. Front Oncol. 2019;9:1421.","journal-title":"Front Oncol"},{"key":"4020_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/cdd.2017.161","volume":"25","author":"JM Adams","year":"2018","unstructured":"Adams JM, Cory S. The BCL-2 arbiters of apoptosis and their growing role as cancer targets. Cell Death Differ. 2018;25:27\u201336.","journal-title":"Cell Death Differ."},{"key":"4020_CR19","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ccell.2018.11.004","volume":"34","author":"D Merino","year":"2018","unstructured":"Merino D, Kelly GL, Lessene G, Wei AH, Roberts AW, Strasser A. BH3-mimetic drugs: blazing the trail for new cancer medicines. Cancer Cell. 2018;34:879\u201391.","journal-title":"Cancer Cell"},{"key":"4020_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1053\/jhep.2001.25387","volume":"34","author":"T Takehara","year":"2001","unstructured":"Takehara T, Liu X, Fujimoto J, Friedman SL, Takahashi H. Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology. 2001;34:55\u201361.","journal-title":"Hepatology"},{"key":"4020_CR21","first-page":"515","volume":"21","author":"J Watanabe","year":"2002","unstructured":"Watanabe J, Kushihata F, Honda K, Mominoki K, Matsuda S, Kobayashi N. Bcl-xL overexpression in human hepatocellular carcinoma. Int J Oncol. 2002;21:515\u20139.","journal-title":"Int J Oncol"},{"key":"4020_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.304","volume":"8","author":"AR Delbridge","year":"2017","unstructured":"Delbridge AR, Aubrey BJ, Hyland C, Bernardini JP, Di Rago L, Garnier JM, et al. The BH3-only proteins BIM and PUMA are not critical for the reticulocyte apoptosis caused by loss of the pro-survival protein BCL-XL. Cell Death Dis. 2017;8:e2914.","journal-title":"Cell Death Dis"},{"key":"4020_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02910-2","volume":"11","author":"A Muenchow","year":"2020","unstructured":"Muenchow A, Weller S, Hinterleitner C, Malenke E, Bugl S, Wirths S, et al. The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA. Cell Death Dis. 2020;11:701.","journal-title":"Cell Death Dis"},{"key":"4020_CR24","doi-asserted-by":"publisher","first-page":"16701","DOI":"10.18632\/oncotarget.24673","volume":"9","author":"A Tutusaus","year":"2018","unstructured":"Tutusaus A, Stefanovic M, Boix L, Cucarull B, Zamora A, Blasco L, et al. Antiapoptotic BCL-2 proteins determine sorafenib\/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma. Oncotarget. 2018;9:16701\u201317.","journal-title":"Oncotarget"},{"key":"4020_CR25","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/sj.cdd.4402081","volume":"14","author":"H Zhang","year":"2007","unstructured":"Zhang H, Nimmer PM, Tahir SK, Chen J, Fryer RM, Hahn KR, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 2007;14:943\u201351.","journal-title":"Cell Death Differ"},{"key":"4020_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03092-7","volume":"11","author":"AL Scherr","year":"2020","unstructured":"Scherr AL, Mock A, Gdynia G, Schmitt N, Heilig CE, Korell F, et al. Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer. Cell Death Dis. 2020;11:875.","journal-title":"Cell Death Dis"},{"key":"4020_CR27","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.4049\/jimmunol.168.3.1356","volume":"168","author":"E Cretney","year":"2002","unstructured":"Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol. 2002;168:1356\u201361.","journal-title":"J Immunol."},{"key":"4020_CR28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1084\/jem.20011171","volume":"195","author":"K Takeda","year":"2002","unstructured":"Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 2002;195:161\u20139.","journal-title":"J. Exp. Med"},{"key":"4020_CR29","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.4049\/jimmunol.175.9.5586","volume":"175","author":"N Zerafa","year":"2005","unstructured":"Zerafa N, Westwood JA, Cretney E, Mitchell S, Waring P, Iezzi M, et al. Cutting edge: TRAIL deficiency accelerates hematological malignancies. J Immunol. 2005;175:5586\u201390.","journal-title":"J Immunol."},{"key":"4020_CR30","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/sj.cr.7290311","volume":"15","author":"RA Daniels","year":"2005","unstructured":"Daniels RA, Turley H, Kimberley FC, Liu XS, Mongkolsapaya J, Ch\u2019En P, et al. Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res. 2005;15:430\u20138.","journal-title":"Cell Res"},{"key":"4020_CR31","doi-asserted-by":"publisher","first-page":"8502","DOI":"10.1158\/0008-5472.CAN-04-2599","volume":"64","author":"C Hao","year":"2004","unstructured":"Hao C, Song JH, Hsi B, Lewis J, Song DK, Petruk KC, et al. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res. 2004;64:8502\u20136.","journal-title":"Cancer Res"},{"key":"4020_CR32","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/91000","volume":"7","author":"K Ichikawa","year":"2001","unstructured":"Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med. 2001;7:954\u201360.","journal-title":"Nat Med"},{"key":"4020_CR33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/5517","volume":"5","author":"H Walczak","year":"1999","unstructured":"Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5:157\u201363.","journal-title":"Nat Med"},{"key":"4020_CR34","doi-asserted-by":"crossref","unstructured":"Phillips DC, Buchanan FG, Cheng D, Solomon LR, Xiao Y, Xue J, et al. Hexavalent TRAIL fusion protein eftozanermin alfa optimally clusters apoptosis-inducing TRAIL receptors to induce on-target antitumor activity in solid tumors. Cancer Res. 2021;81:3402\u201314.","DOI":"10.1158\/0008-5472.CAN-20-2178"},{"key":"4020_CR35","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/hep.26082","volume":"57","author":"K Wahl","year":"2013","unstructured":"Wahl K, Siegemund M, Lehner F, Vondran F, Nussler A, Langer F, et al. Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib. Hepatology. 2013;57:625\u201336.","journal-title":"Hepatology"},{"key":"4020_CR36","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1124\/pr.57.2.6","volume":"57","author":"U Fischer","year":"2005","unstructured":"Fischer U, Schulze-Osthoff K. New approaches and therapeutics targeting apoptosis in disease. Pharm Rev. 2005;57:187\u2013215.","journal-title":"Pharm Rev."},{"key":"4020_CR37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/hep.20747","volume":"42","author":"N Seidel","year":"2005","unstructured":"Seidel N, Volkmann X, L\u00e4nger F, Flemming P, Manns MP, Schulze-Osthoff K, et al. The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum. Hepatology. 2005;42:113\u201320.","journal-title":"Hepatology"},{"key":"4020_CR38","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1002\/hep.21846","volume":"46","author":"X Volkmann","year":"2007","unstructured":"Volkmann X, Fischer U, Bahr MJ, Ott M, Lehner F, Macfarlane M, et al. Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology. 2007;46:1498\u2013508.","journal-title":"Hepatology"},{"key":"4020_CR39","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/cdd.2008.16","volume":"15","author":"EM Michalak","year":"2008","unstructured":"Michalak EM, Villunger A, Adams JM, Strasser A. In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute. Cell Death Differ. 2008;15:1019\u201329.","journal-title":"Cell Death Differ."},{"key":"4020_CR40","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S1097-2765(01)00214-3","volume":"7","author":"K Nakano","year":"2001","unstructured":"Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell. 2001;7:683\u201394.","journal-title":"Mol Cell"},{"key":"4020_CR41","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1126\/science.288.5468.1053","volume":"288","author":"E Oda","year":"2000","unstructured":"Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 2000;288:1053\u20138.","journal-title":"Science"},{"key":"4020_CR42","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S0168-8278(99)80245-1","volume":"31","author":"B Bhardwaj","year":"1999","unstructured":"Bhardwaj B, Bhardwaj G, Lau JY. Expression of p21 and p27 in hepatoma cell lines with different p53 gene profile. J Hepatol. 1999;31:386.","journal-title":"J Hepatol."},{"key":"4020_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4143\/crt.2005.37.1.1","volume":"37","author":"JL Ku","year":"2005","unstructured":"Ku JL, Park JG. Biology of SNU cell lines. Cancer Res Treat. 2005;37:1\u201319.","journal-title":"Cancer Res Treat"},{"key":"4020_CR44","doi-asserted-by":"publisher","first-page":"e0214847","DOI":"10.1371\/journal.pone.0214847","volume":"14","author":"A Willms","year":"2019","unstructured":"Willms A, Schittek H, Rahn S, Sosna J, Mert U, Adam D, et al. Impact of p53 status on TRAIL-mediated apoptotic and non-apoptotic signaling in cancer cells. PLoS One. 2019;14:e0214847.","journal-title":"PLoS One"},{"key":"4020_CR45","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3390\/cancers12020332","volume":"12","author":"B Cucarull","year":"2020","unstructured":"Cucarull B, Tutusaus A, Sub\u00edas M, Stefanovic M, Hern\u00e1ez-Alsina T, Boix L, et al. Regorafenib alteration of the BCL-xL\/MCL-1 ratio provides a therapeutic opportunity for BH3-mimetics in hepatocellular carcinoma models. Cancers. 2020;12:332.","journal-title":"Cancers"},{"key":"4020_CR46","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1002\/hep.23836","volume":"52","author":"H Hikita","year":"2010","unstructured":"Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, Iwase K, et al. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hepatology. 2010;52:1310\u201321.","journal-title":"Hepatology"},{"key":"4020_CR47","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1111\/bph.12659","volume":"171","author":"J Li","year":"2014","unstructured":"Li J, Chen Y, Wan J, Liu X, Yu C, Li W. ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1\/WAF1)) in human cancer cells. Br J Pharm. 2014;171:3182\u201395.","journal-title":"Br J Pharm"},{"key":"4020_CR48","doi-asserted-by":"publisher","first-page":"6089","DOI":"10.1182\/blood-2011-09-378141","volume":"119","author":"M Rahmani","year":"2012","unstructured":"Rahmani M, Aust MM, Attkisson E, Williams DC Jr., Ferreira-Gonzalez A, Grant S. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood. 2012;119:6089\u201398.","journal-title":"Blood"},{"key":"4020_CR49","doi-asserted-by":"publisher","first-page":"25003","DOI":"10.1074\/jbc.M802511200","volume":"283","author":"JH Song","year":"2008","unstructured":"Song JH, Kandasamy K, Kraft AS. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem. 2008;283:25003\u201313.","journal-title":"J Biol Chem"},{"key":"4020_CR50","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00280-011-1763-0","volume":"69","author":"G Wang","year":"2012","unstructured":"Wang G, Zhan Y, Wang H, Li W. ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein. Cancer Chemother Pharm. 2012;69:799\u2013805.","journal-title":"Cancer Chemother Pharm"},{"key":"4020_CR51","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2015.06.001","volume":"63","author":"AL Cheng","year":"2015","unstructured":"Cheng AL, Kang YK, He AR, Lim HY, Ryoo BY, Hung CH, et al. Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: a phase 2 randomized study. J Hepatol. 2015;63:896\u2013904.","journal-title":"J Hepatol"},{"key":"4020_CR52","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/annonc\/mdw004","volume":"27","author":"T Ciuleanu","year":"2016","unstructured":"Ciuleanu T, Bazin I, Lungulescu D, Miron L, Bondarenko I, Deptala A, et al. A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma. Ann Oncol. 2016;27:680\u20137.","journal-title":"Ann Oncol."},{"key":"4020_CR53","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/leu.2011.287","volume":"26","author":"M Konopleva","year":"2012","unstructured":"Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B, et al. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1\/BIM complex. Leukemia. 2012;26:778\u201387.","journal-title":"Leukemia"},{"key":"4020_CR54","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jhep.2009.10.008","volume":"52","author":"H Huynh","year":"2010","unstructured":"Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Toh HC, et al. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). J Hepatol. 2010;52:79\u201387.","journal-title":"J Hepatol"},{"key":"4020_CR55","doi-asserted-by":"publisher","first-page":"24882","DOI":"10.1074\/jbc.M111.255828","volume":"286","author":"TC Albershardt","year":"2011","unstructured":"Albershardt TC, Salerni BL, Soderquist RS, Bates DJ, Pletnev AA, Kisselev AF, et al. Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA. J Biol Chem. 2011;286:24882\u201395.","journal-title":"J Biol Chem"},{"key":"4020_CR56","doi-asserted-by":"publisher","first-page":"118987","DOI":"10.1016\/j.bbamcr.2021.118987","volume":"1868","author":"S Kehr","year":"2021","unstructured":"Kehr S, Vogler M. It\u2019s time to die: BH3 mimetics in solid tumors. Biochim Biophys Acta Mol Cell Res. 2021;1868:118987.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"4020_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.6","volume":"5","author":"W Nakajima","year":"2014","unstructured":"Nakajima W, Hicks MA, Tanaka N, Krystal GW, Harada H. Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer. Cell Death Dis. 2014;5:e1052.","journal-title":"Cell Death Dis"},{"key":"4020_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2588-8","volume":"11","author":"R Florent","year":"2020","unstructured":"Florent R, Weiswald LB, Lambert B, Brotin E, Abeilard E, Louis MH, et al. Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor trametinib. Cell Death Dis. 2020;11:380.","journal-title":"Cell Death Dis"},{"key":"4020_CR59","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/jcp.22843","volume":"227","author":"J Fernando","year":"2012","unstructured":"Fernando J, Sancho P, Fern\u00e1ndez-Rodriguez CM, Lled\u00f3 JL, Caja L, Campbell JS, et al. Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli. J Cell Physiol. 2012;227:1319\u201325.","journal-title":"J Cell Physiol."},{"key":"4020_CR60","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2011-01-327197","volume":"118","author":"AA Morales","year":"2011","unstructured":"Morales AA, Kurtoglu M, Matulis SM, Liu J, Siefker D, Gutman DM, et al. Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL\/Bcl-2 in Mcl-1-expressing myeloma cells. Blood. 2011;118:1329\u201339.","journal-title":"Blood"},{"key":"4020_CR61","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/hep.21467","volume":"45","author":"S Boyault","year":"2007","unstructured":"Boyault S, Rickman DS, de Reyni\u00e8s A, Balabaud C, Rebouissou S, Jeannot E, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2007;45:42\u201352.","journal-title":"Hepatology"},{"key":"4020_CR62","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jhep.2019.06.001","volume":"71","author":"J Calderaro","year":"2019","unstructured":"Calderaro J, Ziol M, Paradis V, Zucman-Rossi J. Molecular and histological correlations in liver cancer. J Hepatol. 2019;71:616\u201330.","journal-title":"J Hepatol"},{"key":"4020_CR63","doi-asserted-by":"publisher","first-page":"e75414","DOI":"10.1371\/journal.pone.0075414","volume":"8","author":"J Abdulghani","year":"2013","unstructured":"Abdulghani J, Allen JE, Dicker DT, Liu YY, Goldenberg D, Smith CD, et al. Sorafenib sensitizes solid tumors to Apo2L\/TRAIL and Apo2L\/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis. PLoS One. 2013;8:e75414.","journal-title":"PLoS One"},{"key":"4020_CR64","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jcmgh.2020.02.009","volume":"10","author":"T Hashiba","year":"2020","unstructured":"Hashiba T, Yamashita T, Okada H, Nio K, Hayashi T, Asahina Y, et al. Inactivation of transcriptional repressor capicua confers sorafenib resistance in human hepatocellular carcinoma. Cell Mol Gastroenterol Hepatol. 2020;10:269\u201385.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"4020_CR65","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/nm.3679","volume":"20","author":"R Rudalska","year":"2014","unstructured":"Rudalska R, Dauch D, Longerich T, McJunkin K, Wuestefeld T, Kang TW, et al. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat Med. 2014;20:1138\u201346.","journal-title":"Nat Med"},{"key":"4020_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.557","volume":"5","author":"R Sonntag","year":"2014","unstructured":"Sonntag R, Gassler N, Bangen JM, Trautwein C, Liedtke C. Pro-apoptotic Sorafenib signaling in murine hepatocytes depends on malignancy and is associated with PUMA expression in vitro and in vivo. Cell Death Dis. 2014;5:e1030.","journal-title":"Cell Death Dis"},{"key":"4020_CR67","doi-asserted-by":"publisher","first-page":"e101386","DOI":"10.1371\/journal.pone.0101386","volume":"9","author":"M Kleine","year":"2014","unstructured":"Kleine M, Riemer M, Krech T, DeTemple D, J\u00e4ger MD, Lehner F, et al. Explanted diseased livers\u2014a possible source of metabolic competent primary human hepatocytes. PLoS One. 2014;9:e101386.","journal-title":"PLoS One"},{"key":"4020_CR68","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1182\/blood-2007-02-073213","volume":"110","author":"K Janssen","year":"2007","unstructured":"Janssen K, Pohlmann S, J\u00e4nicke RU, Schulze-Osthoff K, Fischer U. Apaf-1 and caspase-9 deficiency prevents apoptosis in a Bax-controlled pathway and promotes clonogenic survival during paclitaxel treatment. Blood. 2007;110:3662\u201372.","journal-title":"Blood"},{"key":"4020_CR69","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1007\/s00204-020-02837-9","volume":"94","author":"F Wandrer","year":"2020","unstructured":"Wandrer F, Frangez Z, Liebig S, John K, Vondran F, Wedemeyer H, et al. Autophagy alleviates amiodarone-induced hepatotoxicity. Arch Toxicol. 2020;94:3527\u201339.","journal-title":"Arch Toxicol"},{"key":"4020_CR70","doi-asserted-by":"publisher","first-page":"7065","DOI":"10.1158\/0008-5472.CAN-04-1082","volume":"64","author":"F Essmann","year":"2004","unstructured":"Essmann F, Engels IH, Totzke G, Schulze-Osthoff K, J\u00e4nicke RU. Apoptosis resistance of MCF-7 breast carcinoma cells to ionizing radiation is independent of p53 and cell cycle control but caused by the lack of caspase-3 and a caffeine-inhibitable event. Cancer Res. 2004;64:7065\u201372.","journal-title":"Cancer Res"},{"key":"4020_CR71","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/hep.27250","volume":"60","author":"K John","year":"2014","unstructured":"John K, Hadem J, Krech T, Wahl K, Manns MP, Dooley S, et al. MicroRNAs play a role in spontaneous recovery from acute liver failure. Hepatology. 2014;60:1346\u201355.","journal-title":"Hepatology"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-04020-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-04020-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-04020-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T08:04:16Z","timestamp":1675584256000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-04020-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,26]]},"references-count":71,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["4020"],"URL":"https:\/\/doi.org\/10.1038\/s41419-021-04020-z","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,26]]},"assertion":[{"value":"8 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Ethics Committee of Hannover Medical School, #252-2008, in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"736"}}